Clinical trials: Intracranial Hemorrhage
Subdural Hematoma, Chronic
The SQUID Trial for the Embolization of the Middle Meningeal Artery for Treatment of Chronic Subdural Hematoma (STEM)
STEM Study is a pivotal, international, multi-center, prospective, randomized (1:1) controlled trial designed to provide an assessment of the safety and effectiveness of Middle Meningeal Artery (MMA) embolization with SQUID for…
- Trial name
- STEM (NCT04410146)
- Testing
- SQUID Embolization, SQUID Embolization and Surgical Evacuation, Surgical Evacuation
- Where
- 32 sites in United States, France and 2 more
- Volunteers
- 319 people
- Sponsor
- Balt USA
Subarachnoid Hemorrhage
FILtration of Subarachnoid Hemorrhage Via SpinaL CAtheteR Extension
The objective of this study is to further demonstrate safety and characterize effectiveness of the Neurapheresis™ System (extracorporeal system and catheter) to remove red blood cells (RBCs) and lysed blood by-products from…
- Trial name
- PILLAR-XT (NCT03607825)
- Testing
- Neurapheresis System
- Where
- 4 sites in United States
- Volunteers
- 33 people
- Sponsor
- Minnetronix
Subarachnoid Hemorrhage, Aneurysmal
Safety and Efficacy of Non-invasive Vagus Nerve Stimulation in the Treatment of Headache in Subarachnoid Hemorrhage
This is a single site, randomized, sham-controlled, double blinded pilot study assessing the feasibility, safety, tolerability, and efficacy of non-invasive VNS (nVNS), gammaCore, in the treatment of headache in subarachnoid…
- Trial name
- VANQUISH (NCT04126408)
- Testing
- gammaCore
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Northwell Health
Intracerebral Hemorrhage
Safety and Tolerability of PF-05230907 in Intracerebral Hemorrhage
This study employs a modified continual reassessment method (mCRM) design to estimate the maximum tolerated dose (MTD) of PF-05230907, defined as a target toxicity rate of 15% based on treatment emergent thromboembolic and/or…
- Trial name
- NCT02687191
- Testing
- PF-05230907
- Where
- 13 sites in United States, Canada and 2 more
- Volunteers
- 21 people
- Sponsor
- Pfizer
Intracerebral Hemorrhage
Intracerebral Hemorrhage Deferoxamine Trial - iDEF Ttrial
The investigators hypothesize that treatment with the iron chelator, Deferoxamine Mesylate, improves the outcome of patients with brain hemorrhage.
- Trial name
- NCT02175225
- Testing
- Deferoxamine Mesylate
- Where
- 28 sites in United States, Canada
- Volunteers
- 294 people
- Sponsor
- Beth Israel Deaconess Medical Center
Intracerebral Hemorrhage
Simvastatin For Intracerebral Hemorrhage Study
Study Objective: To analyze if statins are effective in ameliorating perihematomal edema evolution thereby reducing mortality and improving functional outcomes following spontaneous intracerebral hemorrhage (ICH).
- Trial name
- NCT00718328
- Testing
- Simvastatin 80 mg
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Johns Hopkins University
Subarachnoid Hemorrhage
Treatment of Subarachnoid Hemorrhage With Human Albumin
The purpose of this study is to evaluate the tolerability and safety of 25 percent human albumin therapy in patients with subarachnoid hemorrhage.
- Trial name
- NCT00283400
- Testing
- 25% human albumin
- Where
- 6 sites in United States, Canada
- Volunteers
- 47 people
- Sponsor
- Baylor College of Medicine
Intracerebral Hemorrhage, Ischemic Stroke
Field Administration of Stroke Therapy-Blood Pressure Lowering
This is an open, pilot, dose-escalation study of glyceryl trinitrate (GTN, Nitroglycerin) administered by paramedics in the field within 2 hours of symptom onset to 45 severely hypertensive stroke patients.
- Trial name
- FAST-BP (NCT01811693)
- Testing
- Glycerly Trinitrate
- Where
- 2 sites in United States
- Volunteers
- 4 people
- Sponsor
- University of California, Los Angeles
Cerebral Vasospasm
Safety Study of Nicardipine to Treat Cerebral Vasospasm
The purpose of this study is to determine if intrathecal nicardipine is safe for the treatment of cerebral vasospasm.
- Trial name
- NCT01810302
- Testing
- Nicardipine hydrochloride, Preservative-free normal saline
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- University of Florida
Intracerebral Hemorrhage
Antihypertensive Treatment of Acute Cerebral Hemorrhage-II
The specific aims of this study are to: 1. Definitively determine the therapeutic benefit of the intensive treatment relative to the standard treatment in the proportion of patients with death and disability (mRS 4-6) at 3 months…
- Trial name
- ATACH-II (NCT01176565)
- Testing
- Intravenous nicardipine hydrochloride
- Where
- 171 sites in United States, Canada and 5 more
- Volunteers
- 1,000 people
- Sponsor
- University of Minnesota
Acute Intracranial Hemorrhage
Trial of Andexanet Alfa in ICrH Patients Receiving an Oral FXa Inhibitor
Randomized, controlled clinical trial evaluating the efficacy and safety of andexanet alfa versus usual care in patients with intracranial hemorrhage anticoagulated with a direct oral FXa anticoagulant
- Trial name
- NCT03661528
- Testing
- andexanet alfa, Usual Care
- Where
- 142 sites in United States, Austria and 22 more
- Volunteers
- 530 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Subarachnoid Hemorrhage, Aneurysmal
Induced Suppression of Platelets Activity in Aneurysmal SAH Management (iSPASM)
This is a phase 1/2a, randomized, double blind, single-center study comparing standard care alone to standard care with Aggrastat in patients diagnosed with aneurysmal subarachnoid hemorrhage.
- Trial name
- NCT03691727
- Testing
- tirofiban hydrochloride (AGGRASTAT®), MRI, Neurological Exam
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- David Hasan
Intracerebral Hemorrhage
A Pilot Study of Minocycline in Intracerebral Hemorrhage Patients
The MACH Trial is a pilot study of 400mg minocycline over five days in acute intracerebral hemorrhage patients. The study will evaluation the safety and efficacy of minocycline in intracerebral hemorrhage patients.
- Trial name
- MACH (NCT01805895)
- Testing
- Minocycline
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Augusta University
Intracerebral Haemorrhage, Intraventricular
Safety and Suitability of Supplementing Early MIP Surgery (MIPS) of ICH With Pioglitazone
This is an exploratory single-center prospective study of 20 subjects with primary basal ganglia ICH who will receive early MIPS in combination with perioperative pioglitazone treatment.
- Trial name
- ENRICHPLUS (NCT05582707)
- Testing
- Pioglitazone 15mg
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of Maryland, Baltimore